Precision Biosciences Inc (DTIL) Implied Volatility Current

Tracking DTIL implied volatility helps you identify when options premiums on Precision Biosciences Inc are historically cheap or expensive, and where the best trades are hiding. Precision Biosciences Inc implied volatility reflects the market's expectation of future price movement: when DTIL IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Precision Biosciences Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For DTIL, tracking metrics like DTIL IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on DTIL signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.

The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where DTIL implied volatility sits today versus where it has been. Our scanner ranks Precision Biosciences Inc implied volatility against its historical range, surfaces extremes in DTIL IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Precision Biosciences Inc IV is rich or cheap — measure it, then act on it.